TY - JOUR
T1 - Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
AU - Viet, Chi T.
AU - Asam, Kesava R.
AU - Yu, Gary
AU - Dyer, Emma C.
AU - Kochanny, Sara
AU - Thomas, Carissa M.
AU - Callahan, Nicholas F.
AU - Morlandt, Anthony B.
AU - Cheng, Allen C.
AU - Patel, Ashish A.
AU - Roden, Dylan F.
AU - Young, Simon
AU - Melville, James
AU - Shum, Jonathan
AU - Walker, Paul C.
AU - Nguyen, Khanh K.
AU - Kidd, Stephanie N.
AU - Lee, Steve C.
AU - Folk, Gretchen S.
AU - Viet, Dan T.
AU - Grandhi, Anupama
AU - Deisch, Jeremy
AU - Ye, Yi
AU - Momen-Heravi, Fatemeh
AU - Pearson, Alexander T.
AU - Aouizerat, Bradley E.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Oral squamous cell carcinoma (OSCC) biomarker studies rarely employ multi-omic biomarker strategies and pertinent clinicopathologic characteristics to predict mortality. In this study we determine for the first time a combined epigenetic, gene expression, and histology signature that differentiates between patients with different tobacco use history (heavy tobacco use with ≥10 pack years vs. no tobacco use). Using The Cancer Genome Atlas (TCGA) cohort (n = 257) and an internal cohort (n = 40), we identify 3 epigenetic markers (GPR15, GNG12, GDNF) and 13 expression markers (IGHA2, SCG5, RPL3L, NTRK1, CD96, BMP6, TFPI2, EFEMP2, RYR3, DMTN, GPD2, BAALC, and FMO3), which are dysregulated in OSCC patients who were never smokers vs. those who have a ≥ 10 pack year history. While mortality risk prediction based on smoking status and clinicopathologic covariates alone is inaccurate (c-statistic = 0.57), the combined epigenetic/expression and histologic signature has a c-statistic = 0.9409 in predicting 5-year mortality in OSCC patients.
AB - Oral squamous cell carcinoma (OSCC) biomarker studies rarely employ multi-omic biomarker strategies and pertinent clinicopathologic characteristics to predict mortality. In this study we determine for the first time a combined epigenetic, gene expression, and histology signature that differentiates between patients with different tobacco use history (heavy tobacco use with ≥10 pack years vs. no tobacco use). Using The Cancer Genome Atlas (TCGA) cohort (n = 257) and an internal cohort (n = 40), we identify 3 epigenetic markers (GPR15, GNG12, GDNF) and 13 expression markers (IGHA2, SCG5, RPL3L, NTRK1, CD96, BMP6, TFPI2, EFEMP2, RYR3, DMTN, GPD2, BAALC, and FMO3), which are dysregulated in OSCC patients who were never smokers vs. those who have a ≥ 10 pack year history. While mortality risk prediction based on smoking status and clinicopathologic covariates alone is inaccurate (c-statistic = 0.57), the combined epigenetic/expression and histologic signature has a c-statistic = 0.9409 in predicting 5-year mortality in OSCC patients.
UR - http://www.scopus.com/inward/record.url?scp=85195638884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85195638884&partnerID=8YFLogxK
U2 - 10.1038/s41698-024-00605-x
DO - 10.1038/s41698-024-00605-x
M3 - Article
C2 - 38851780
AN - SCOPUS:85195638884
SN - 2397-768X
VL - 8
JO - npj Precision Oncology
JF - npj Precision Oncology
IS - 1
M1 - 130
ER -
